Hairy cell leukemia: a specific 17-gene expression signature points to new targets for therapy.
Fiche publication
Date publication
avril 2022
Journal
Journal of cancer research and clinical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBLIQUIS Agathe, Dr DRENOU Bernard
Tous les auteurs :
Maitre E, Cornet E, Debliquis A, Drenou B, Gravey F, Chollet D, Cheze S, Docquier M, Troussard X, Matthes T
Lien Pubmed
Résumé
Hairy cell leukemia (HCL) is a rare chronic B cell malignancy, characterized by infiltration of bone marrow, blood and spleen by typical "hairy cells" that bear the BRAFV600E mutation. However, in addition to the intrinsic activation of the MAP kinase pathway as a consequence of the BRAFV600E mutation, the potential participation of other signaling pathways to the pathophysiology of the disease remains unclear as the precise origin of the malignant hairy B cells.
Mots clés
EBI3, Gene expression, Hairy cell leukemia, NF-KB pathway, RGS13
Référence
J Cancer Res Clin Oncol. 2022 Apr 27;: